Irbesartan, hydrochlorothiazide.
Each caplet contains: Irbesartan 300 mg; Hydrochlorothiazide 12.5 mg.
Treatment of essential hypertension.
The fixed dose combination is indicated in patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.
Adult: The usual recommended intial and maintenance dose is Irtan Plus once daily.
Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, Irtan Plus may be administered with another antihypertensive drug.
Due to the hydrochlorothiazide component, Irtan Plus is not recommended for patients with severe renal dysfunction (creatinine clearance <30 mL/min).
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥30 ml/min.
Hepatic impairment and elderly patients.
Hypersensitivity to Angiotensin-II blocker. Pregnancy.
Due to the hydrochlorothiazide component, Irtan Plus is not recommended for patients with severe renal dysfunction (creatinine clearance <30 mL/min).
Patient's condition with volume and/or sodium depletion should be corrected before initiating therapy with Irtan Plus.
Headache, dizziness, fatigue, nausea.
Other antihypertensive agents: The antihypertensive effect of Irtan Plus may be increased.
NSAIDs: may reduce the diuretic, natriuteric and antihypertensive effects of thiazide diuretic.
Store in a dry place, below 30°C.
C09DA04 - irbesartan and diuretics ; Belongs to the class of angiotensin II receptor blockers (ARBs) in combination with diuretics. Used in the treatment of cardiovascular disease.
Irtan Plus caplet
3 × 10's (Rp270,000/boks)
Sign Out
